Tg Therapeutics (TGTX) Research & Development (2011 - 2026)

Tg Therapeutics' Research & Development history runs 16 years deep, the most recent figure standing at $43.5 million for Q1 2026.

• On a quarterly basis, Research & Development fell 6.13% year-over-year to $43.5 million in Q1 2026; TTM through Mar 2026 was $152.0 million, a 45.12% increase from a year earlier, with the FY2025 full-year figure at $160.2 million, up 92.73% from the prior year.
• Research & Development climbed to $43.5 million in Q1 2026 per TGTX's latest filing, from $41.2 million in the prior quarter.
• Across five years, Research & Development topped out at $48.0 million in Q1 2022 and bottomed at $11.8 million in Q3 2023.
• The 5-year median for Research & Development is $26.9 million (2022), against an average of $27.9 million.
• Across the five-year window, Research & Development sank 71.54% in 2022 and surged 106.19% in 2024, its largest moves.
• Year by year, Research & Development stood at $16.4 million in 2022, then advanced by 6.33% to $17.4 million in 2023, then increased by 18.71% to $20.7 million in 2024, then soared by 98.87% to $41.2 million in 2025, then grew by 5.65% to $43.5 million in 2026.
• Per Business Quant, the three latest TGTX Research & Development figures stand at $43.5 million (Q1 2026), $41.2 million (Q4 2025), and $35.5 million (Q3 2025).